Sakari Nieminen

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 292 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · Diabetes Care · 2018 · 238 citations

Medicine, Pharmacology, Pharmacotherapy +17

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat et al. · Annals of Internal Medicine · 2023 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +17